Pharma BD Deal Intelligence
Roche converts a five-year partnership into full ownership: $750M upfront (up to $1.05B total) buys PathAI's AI pathology platform outright for its Diagnostics division, though the deal still awaits regulatory clearance and an H2 2026 close.
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →Roche Holding will acquire AI digital pathology company PathAI in a deal worth up to $1.05 billion, including $750 million upfront and up to $300 million in…
Roche has agreed to shell out up to $1.05 billion to acquire PathAI, the Boston-based artificial intelligence company whose machine learning models analyze…
Roche has signed a definitive merger agreement to acquire PathAI in a transaction valued at up to USD 1.05 billion, comprising USD 750 million in upfront cash…
Source summaries from our enrichment pipeline; follow links for originals.
All 6 sources with sentiment breakdown →
Roche entered a definitive merger agreement to acquire PathAI for $750M upfront plus up to $300M in milestones (total up to $1.05B). PathAI's AI-powered digital pathology platform will be integrated into Roche's Diagnostics division to scale companion diagnostic algorithms globally, building on the 2021/2024 partnership. Close expected H2 2026.
2.0M US cases/yr · $1.5B 2025 global digital pathology market, Grand View Research
Companion diagnostics (CDx) are tissue- or blood-based assays required to identify cancer patients whose tumors carry a biomarker matched to a specific targeted therapy. Digital pathology applies whole-slide imaging and AI-driven image analysis to standardize and scale this scoring (e.g., HER2, PD-L1, TROP2), addressing pathologist shortages and inter-rater variability that bottleneck access to precision oncology drugs.
Roche/Ventana already dominates IHC-based CDx and now consolidates the AI layer. Direct competitors include Paige.AI (Mount Sinai spinout, FDA-cleared Paige Prostate), Ibex Medical Analytics, Proscia, Indica Labs, and Philips IntelliSite. Owkin and Tempus compete on the multimodal pathology+genomics axis. The deal removes PathAI as an independent partner option for rivals like Bio-Rad, Agilent/Dako, and Leica/Danaher.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Roche Holding AG / PathAI, Inc. (this deal) | 2026 | $1.1B | — |
| Roche Holding AG / Chugai Pharmaceutical Co. Ltd. | 2002 | $1.4B | 100 |
| Roche Holding AG / Ventana Medical Systems Inc. | 2008 | $3.4B | 88 |
| Roche Holding AG / Corange Ltd. (Boehringer Mannheim Group) | 1997 | $11.0B | 88 |
| Roche Holding AG / Ventana Medical Systems Inc. | 2007 | $3.4B | 88 |
| Roche Holding AG / Foundation Medicine, Inc. | 2015 | $1.1B | 87 |
| Roche Holding AG / Foundation Medicine, Inc. | 2018 | $5.3B | 85 |
← Browse all deals · How we score deals
More: 2026 deals · Roche Holding AG deals · Oncology deals